Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find the highest dose of dasatinib that can be safely given
to a patient when the drug is given in combination with the known anticancer drug paclitaxel.
Paclitaxel is an established anti-cancer drug, used in the treatment of many cancers, and it
is an approved treatment for breast cancer. Dasatinib has been approved by the Food and Drug
Administration for use as a single therapy in another kind of cancer, but its use in breast
cancer patients, and in combination with paclitaxel is investigational.
In this study, we will test the safety of dasatinib when given at different dose levels in
combination with paclitaxel. We want to find out what effects, good and/or bad, it has on the
patient and on metastatic breast cancer.